Biomarkers van chronische ontstekingsziekten van de gewrichten.
Suspended
- Conditions
- RA and SpA
- Registration Number
- NL-OMON29523
- Lead Sponsor
- AMC amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
All patients 18 years or older with a diagnosis of chronic inflammatory arthritis e.g. rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, osteoarthritis, crystal arthropathy and undifferentiated arthritis, can be invited to participate in this study
Exclusion Criteria
Not able to give consent.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To identify novel biomarker reflexting cellular and molecular processes of the pathophysiology of chronic inflammatory arthritis, inclusie RA and SpA and to validate these biomarkers.
- Secondary Outcome Measures
Name Time Method Generate a biobank with biological samples and clinical data in RA and SpA for the purpose of the development and validation of novel biomarkers.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers are being evaluated in the AMC Amsterdam observational trial NL-OMON29523 for RA and SpA?
How do cytokine profiles in NL-OMON29523 compare to standard-of-care treatment responses in rheumatoid arthritis patients?
Which genetic or proteomic markers predict differential outcomes in axial versus peripheral spondyloarthritis subtypes within NL-OMON29523?
What are the safety implications of non-invasive biomarker monitoring in chronic inflammatory arthritis compared to traditional methods?
How does the NL-OMON29523 trial's biomarker approach align with emerging therapies targeting IL-17 or JAK pathways in SpA and RA?